ASPREE Trial Registration
death, cardiovascular disease, cancer, NCT01038583Cancer, diabetes
TYPE 2 DIABETES, CARDIOVASCULAR DISEASE, CANCER, DISEASE, INSULIN RESISTANCE, TYPE 2 DIABETES, DIABETES
ClinicalTrials.gov ID NCT01038583Cancer is a leading cause of death worldwide (Type 2 diabetes is a complex disease characterized by β-cell failure in the setting of insulin resistance (Metformin, an oral antihyperglycemic agent, is the recommended first-line treatment for type 2 diabetes in the absence of contraindications (Aspirin is commonly co-prescribed with metformin for prevention of cardiovascular disease in people with diabetes (In this analysis, we aimed to use the randomization of participants to aspirin or placebo in the ASPREE trial to examine in older adults with diabetes 1) the association between metformin and cancer incidence and mortality, 2) the effect of aspirin (vs placebo) in metformin users on cancer incidence and mortality, and 3) whether the effect of aspirin (vs placebo) differs between those who do and do not use metformin.